Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Asensus Surgical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Asensus Surgical wird ein Gewinn- und Umsatzwachstum von 52.8% bzw. 49.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 55.3% pro Jahr wachsen soll.

Wichtige Informationen

52.8%

Wachstumsrate der Gewinne

55.3%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	49.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:ASXC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	51	-26	N/A	N/A	1
12/31/2025	22	-61	N/A	N/A	2
12/31/2024	12	-66	N/A	N/A	2
3/31/2024	9	-79	-61	-60	N/A
12/31/2023	9	-78	-64	-64	N/A
9/30/2023	6	-79	-65	-64	N/A
6/30/2023	7	-80	-65	-64	N/A
3/31/2023	7	-79	-61	-60	N/A
12/31/2022	7	-76	-60	-59	N/A
9/30/2022	7	-74	-59	-58	N/A
6/30/2022	7	-71	-54	-52	N/A
3/31/2022	7	-64	-48	-46	N/A
12/31/2021	8	-62	-42	-41	N/A
9/30/2021	7	-60	-41	-40	N/A
6/30/2021	5	-59	-41	-40	N/A
3/31/2021	5	-60	-45	-44	N/A
12/31/2020	3	-60	-47	-47	N/A
9/30/2020	3	-60	-48	-48	N/A
6/30/2020	4	-143	-59	-59	N/A
3/31/2020	7	-149	-62	-62	N/A
12/31/2019	9	-154	-74	-73	N/A
9/30/2019	15	-147	-73	-72	N/A
6/30/2019	19	-69	-69	-69	N/A
3/31/2019	22	-83	-61	-60	N/A
12/31/2018	24	-62	-49	-48	N/A
9/30/2018	20	-131	-46	-45	N/A
6/30/2018	15	-150	-42	-41	N/A
3/31/2018	10	-130	-47	-46	N/A
12/31/2017	7	-145	N/A	-47	N/A
9/30/2017	4	-83	N/A	-53	N/A
6/30/2017	5	-57	N/A	-50	N/A
3/31/2017	3	-122	N/A	-51	N/A
12/31/2016	2	-120	N/A	-52	N/A
9/30/2016	1	-120	N/A	-51	N/A
6/30/2016	N/A	-121	N/A	-50	N/A
3/31/2016	N/A	-50	N/A	-45	N/A
12/31/2015	N/A	-47	N/A	-39	N/A
9/30/2015	0	-41	N/A	-34	N/A
6/30/2015	0	-39	N/A	-36	N/A
3/31/2015	0	-40	N/A	-35	N/A
12/31/2014	0	-38	N/A	-33	N/A
9/30/2014	0	-38	N/A	-31	N/A
6/30/2014	1	-37	N/A	-27	N/A
3/31/2014	1	-31	N/A	-24	N/A
12/31/2013	1	-28	N/A	-21	N/A
9/30/2013	2	-24	N/A	-17	N/A
6/30/2013	2	-16	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ASXC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ASXC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ASXC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ASXCDie Einnahmen des Unternehmens (49.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: ASXCDie Einnahmen des Unternehmens (49.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ASXC in 3 Jahren voraussichtlich hoch sein wird

Asensus Surgical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 20%

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Consensus EPS estimates fall by 23%

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Asensus Surgical, Inc. to Report Q1, 2024 Results on May 14, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Full year 2023 earnings: EPS exceeds analyst expectations

Asensus Surgical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

President exercised options and sold US$131k worth of stock

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Asensus Surgical, Inc. Develops the LUNA Surgical System

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Asensus Surgical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Asensus Surgical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Share price stability

Consensus EPS estimates fall by 23%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Full year 2022 earnings: EPS exceeds analyst expectations

President exercised options and sold US$406k worth of stock

Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Consensus revenue estimates fall by 17%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$2.25

Asensus Surgical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Asensus Surgical, Inc. Announces Impairment Charges for Three Months Ended June 30, 2022

Asensus Surgical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Asensus Surgical, Inc. to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery Conference

Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022

Asensus Surgical, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Asensus Surgical, Inc. Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision Capabilities

Asensus Surgical, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Asensus Surgical Announces FDA Clearance in General Surgery

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million.

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million.

TransEnterix, Inc. Announces Southern Surgical Hospital to Initiate a Senhance Digital Laparoscopic Program

TransEnterix Announces Approval of Senhance Surgical System in Russian Federation

Transenterix, Inc. Does Not Provide Forward-Looking Guidance

TransEnterix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

TransEnterix, Inc. Announces First Pediatric Surgical Cases with Senhance® Surgical System

TransEnterix Announces Toshima Hospital in Japan to Initiate A Senhance® Digital Laparoscopy Program

Transenterix, Inc. Not Provide Revenue Guidance

TransEnterix, Inc. Contemplates Bankruptcy

TransEnterix, Inc. to Report Q2, 2020 Results on Aug 05, 2020

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken